{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-006270","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.807005+00:00","generated_at":"2026-06-18T04:46:33.659733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clene reports FY2022 net loss of $29.9M; highlights positive clinical data in ALS and MS","bullets":["Net loss $29.9M ($0.46/share) vs $9.7M ($0.16) prior year; cash $23.3M, runway into Q3 2023.","HEALEY ALS trial: CNM-Au8 associated with 74% lower risk of clinical worsening at 6 months; 98% reduced risk of death/permanent ventilation.","RESCUE-ALS OLE: significant ALSFRS-R preservation from randomization to 48 weeks (p=0.0159).","VISIONARY-MS trial: significant improvements in visual evoked potential and MRI measures supporting neuroprotection.","Plans to meet FDA in Q3 2023 for end-of-Phase 2 meetings for ALS and MS; secured $25M equity facility with Lincoln Park."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-006270","json":"https://secwatch.observer/filing/0001437749-23-006270.json","markdown":"https://secwatch.observer/filing/0001437749-23-006270.md","text":"https://secwatch.observer/filing/0001437749-23-006270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/0001437749-23-006270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/clnn20221214_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:46:33.659733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a14ad3a6569319582b140612f7aa5971754393a","claim":"Clene Inc. reported financial results for full year ended December 31, 2022.","evidence_excerpt":"On March 13, 2023, Clene Inc. (the “Company”) issued a press release announcing its full year operating and financial results for its year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/0001437749-23-006270-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}